Xncef-CV 500 Tablet is a combination antibiotic formulation containing Cefuroxime 500 mg and Clavulanic Acid 125 mg, designed to combat a broad spectrum of bacterial infections. Cefuroxime, a second-generation cephalosporin, exerts its bactericidal action by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefuroxime by preventing the enzymatic degradation of the antibiotic by beta-lactamase-producing bacteria, thereby extending its spectrum of activity against resistant strains. This combination is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, and sinusitis caused by susceptible organisms. Xncef-CV 500 Tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on the severity of infection and renal function. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypersensitivity reactions in susceptible individuals. Caution is advised in patients with a history of penicillin or cephalosporin allergy. The use of Xncef-CV 500 Tablet should be guided by culture and sensitivity results whenever possible to minimize the development of antibiotic resistance.